TXMD · XBRL financial data
TherapeuticsMD financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (TXMD's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | 70 | 1 | 2 | — |
| Revenue from contracts with customers | 65 | 87 | 70 | — | — | — |
| Cost of goods and services sold | 16 | 19 | 1 | — | — | — |
| Gross profit | 49 | 68 | 69 | 1 | — | — |
| Research and development | 10 | 7 | — | — | — | — |
| Selling, general and administrative | 193 | — | — | 9 | 5 | — |
| General and administrative | 77 | 93 | 58 | 9 | 6 | 7 |
| Total operating expenses | 204 | 208 | 67 | 10 | 7 | 7 |
| Operating income (loss) | (156) | (140) | 1 | (9) | (5) | (4) |
| Interest income | — | — | — | — | 0 | 0 |
| Interest expense | 29 | 33 | 36 | 0 | 0 | 0 |
| Other income (expense) | — | 0 | (0) | — | — | — |
| Income tax expense (benefit) | — | — | — | (0) | (0) | — |
| Net income (loss) | (184) | (172) | 112 | (10) | (2) | (1) |
| Earnings per share, basic USD per share | — | (21.66) | 12.41 | (0.98) | (0.19) | (0.05) |
| Earnings per share, diluted USD per share | — | (21.66) | 11.96 | (0.98) | (0.19) | (0.05) |
| Weighted average shares, basic‡ millions of shares | 6 | 8 | 9 | 10 | 0 | 12 |
| Weighted average shares, diluted millions of shares | — | 8 | 9 | 10 | 0 | 12 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (December 2022); filings made before it reported them unadjusted.
Balance sheet
CSVFiscal years (TXMD's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 80 | 65 | 65 | 4 | 5 | 7 |
| Accounts receivable | 32 | 36 | — | — | — | — |
| Inventory | 8 | 8 | — | — | — | — |
| Prepaid and other current assets | 8 | 11 | 6 | 4 | 4 | 3 |
| Total current assets | 128 | 119 | 55 | 12 | 12 | 14 |
| Property and equipment, net | 2 | 1 | 0 | — | — | — |
| Right-of-use asset | 10 | 8 | 8 | 7 | 6 | 5 |
| Total assets | 182 | 169 | 90 | 43 | 39 | 38 |
| Accounts payable | 21 | 20 | 2 | 0 | 0 | 0 |
| Current portion of long-term debt | — | 188 | — | — | — | — |
| Total current liabilities | 59 | 253 | 47 | 7 | 5 | 5 |
| Long-term debt | 238 | 0 | — | — | — | — |
| Lease liability, non-current | 9 | 8 | 7 | 7 | 6 | 5 |
| Total liabilities | 306 | 263 | 55 | 14 | 11 | 11 |
| Accumulated deficit | (879) | (1,051) | (939) | (950) | (952) | (952) |
| Total stockholders' equity | (124) | (94) | 35 | 29 | 27 | 27 |
| Total liabilities and equity | 182 | 169 | 90 | 43 | 39 | 38 |
| Common shares outstanding (cover page)‡ millions of shares | 8 | 9 | 10 | 12 | 12 | 12 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (December 2022); filings made before it reported them unadjusted.
Cash flows
CSVFiscal years (TXMD's year ends in late December)
| In millions of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (184) | (172) | 112 | (10) | (2) | (1) |
| Stock-based compensation | 11 | 18 | 12 | 1 | 0 | 0 |
| Net cash from operating activities | (159) | (143) | — | — | — | — |
| Purchases of property and equipment | 0 | 0 | — | — | — | — |
| Net cash from investing activities | (2) | (2) | — | — | — | — |
| Proceeds from issuing common stock | 32 | 184 | 2 | 3 | — | — |
| Net cash from financing activities | 81 | 130 | — | 3 | — | — |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| TherapeuticsMD | 9.2 | not reported | not reported | 11.6M | — | 10-QJun 30, 2026 |
| Oncotelic Therapeutics | 0.2 | 0.3 | (0.1)* | 457.5M | 2.0 quarters | 10-QJun 30, 2026 |
| Artelo Biosciences | 4.2 | not reported | (5)* | 4.6M | 0.8 quarters | 10-QJun 30, 2026 |
| Bioxytran | 0.2 | not reported | (0.3)* | 114.7M | 0.5 quarters | 10-QJun 30, 2026 |
| Raphael Pharmaceutical | 0 | not reported | 0* | 20.2M | — | 10-QJun 30, 2026 |
| GT Biopharma | 5 | not reported | (4.3)* | 45.1M | 1.2 quarters | 10-QJun 30, 2026 |
| Alaunos Therapeutics | 0.1 | 0 | (0.3)* | 2.5M | 0.4 quarters | 10-QJun 30, 2026 |
| Biovie | 9 | not reported | (4.1)* | 7.5M | 2.2 quarters | 10-KJun 30, 2026 |
| BioCardia | 4.1 | not reported | (1.7)* | 15.1M | 2.4 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.